PRGO
Perrigo Company plc
Drug Manufacturers - Specialty & Generic
Market Cap$1.61B
5Y Perf.-78.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRGO vs TEVA
Revenue, margins, valuation, and 5-year total return — side by side.
TEVA
Teva Pharmaceutical Industries Limited
Drug Manufacturers - Specialty & Generic
Market Cap$41.93B
5Y Perf.+187.4%
PRGO vs TEVA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRGO | TEVA |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $1.61B | $41.93B |
| Revenue (TTM) | $4.18B | $17.35B |
| Net Income (TTM) | $-1.82B | $1.56B |
| Gross Margin | 34.2% | 52.1% |
| Operating Margin | -4.1% | 13.2% |
| Forward P/E | 5.6x | 14.5x |
| Total Debt | $3.97B | $17.38B |
| Cash & Equiv. | $532M | $3.56B |
PRGO vs TEVA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRGO
TEVA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Perrigo Company plc (PRGO) | 100 | 21.4 | -78.6% |
| Teva Pharmaceutical… (TEVA) | 100 | 287.4 | +187.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRGO vs TEVA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: TEVA leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
PRGO
Perrigo Company plc
The Income Pick
PRGO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 10 yrs, beta 1.18, yield 9.8%
- Lower volatility, beta 1.18, current ratio 2.76x
- Lower P/E (5.6x vs 14.5x)
Best for: income & stability and sleep-well-at-night
TEVA
Teva Pharmaceutical Industries Limited
The Growth Play
TEVA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 4.3%, EPS growth 182.8%, 3Y rev CAGR 5.0%
- -28.3% 10Y total return vs PRGO's -77.7%
- Beta 1.13, current ratio 1.04x
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TEVA | 4.3% revenue growth vs PRGO's -2.8% |
| Value | PRGO | Lower P/E (5.6x vs 14.5x) |
| Quality / Margins | TEVA | 9.0% margin vs PRGO's -43.5% |
| Stability / Safety | TEVA | Beta 1.13 vs PRGO's 1.18 |
| Dividends | PRGO | 9.8% yield; 10-year raise streak; the other pay no meaningful dividend |
| Momentum (1Y) | TEVA | +104.6% vs PRGO's -51.2% |
| Efficiency (ROA) | TEVA | 3.9% ROA vs PRGO's -19.8%, ROIC 7.7% vs 3.7% |
PRGO vs TEVA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
PRGO vs TEVA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLTEVALAGGINGPRGO
PRGOPerrigo Company plc
2leads
TEVATeva Pharmaceutical I…
4leads
6 Total Categories
CATEGORYLEADERvs PRGOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
TEVA6/6
Valuation MetricsMultiples, price ratios, and targets
PRGO6/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
TEVA6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TEVA6/6
Risk & VolatilityBeta, volatility, and downside exposure
TEVA2/2
Analyst OutlookRatings, price targets, and dividends
PRGO1/1
Income & Cash Flow (Last 12 Months)
TEVA leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TEVA is the larger business by revenue, generating $17.3B annually — 4.2x PRGO's $4.2B. TEVA is the more profitable business, keeping 9.0% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, TEVA holds the edge at +2.3% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $4.2B | $17.3B |
| EBITDAEarnings before interest/tax | $58M | $3.3B |
| Net IncomeAfter-tax profit | -$1.8B | $1.6B |
| Free Cash FlowCash after capex | $108M | $1.2B |
| Gross MarginGross profit ÷ Revenue | +34.2% | +52.1% |
| Operating MarginEBIT ÷ Revenue | -4.1% | +13.2% |
| Net MarginNet income ÷ Revenue | -43.5% | +9.0% |
| FCF MarginFCF ÷ Revenue | +2.6% | +6.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -7.2% | +2.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -56.4% | +72.2% |
TEVA leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
PRGO leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, PRGO's 7.4x EV/EBITDA is more attractive than TEVA's 17.6x.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $1.6B | $41.9B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $55.8B |
| Trailing P/EPrice ÷ TTM EPS | -1.14x | 30.01x |
| Forward P/EPrice ÷ next-FY EPS est. | 5.56x | 14.55x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 7.42x | 17.65x |
| Price / SalesMarket cap ÷ Revenue | 0.38x | 2.43x |
| Price / BookPrice ÷ Book value/share | 0.55x | 5.34x |
| Price / FCFMarket cap ÷ FCF | 11.12x | 36.52x |
PRGO leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
TEVA leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
TEVA delivers a 20.7% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $-51 for PRGO. PRGO carries lower financial leverage with a 1.35x debt-to-equity ratio, signaling a more conservative balance sheet compared to TEVA's 2.20x. On the Piotroski fundamental quality scale (0–9), TEVA scores 8/9 vs PRGO's 4/9, reflecting strong financial health.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | -50.7% | +20.7% |
| ROA (TTM)Return on assets | -19.8% | +3.9% |
| ROICReturn on invested capital | +3.7% | +7.7% |
| ROCEReturn on capital employed | +4.3% | +8.0% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 8 |
| Debt / EquityFinancial leverage | 1.35x | 2.20x |
| Net DebtTotal debt minus cash | $3.4B | $13.8B |
| Cash & Equiv.Liquid assets | $532M | $3.6B |
| Total DebtShort + long-term debt | $4.0B | $17.4B |
| Interest CoverageEBIT ÷ Interest expense | -7.20x | 2.51x |
TEVA leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TEVA leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TEVA five years ago would be worth $34,625 today (with dividends reinvested), compared to $3,986 for PRGO. Over the past 12 months, TEVA leads with a +104.6% total return vs PRGO's -51.2%. The 3-year compound annual growth rate (CAGR) favors TEVA at 58.4% vs PRGO's -25.2% — a key indicator of consistent wealth creation.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | -13.5% | +16.3% |
| 1-Year ReturnPast 12 months | -51.2% | +104.6% |
| 3-Year ReturnCumulative with dividends | -58.1% | +297.5% |
| 5-Year ReturnCumulative with dividends | -60.1% | +246.2% |
| 10-Year ReturnCumulative with dividends | -77.7% | -28.3% |
| CAGR (3Y)Annualised 3-year return | -25.2% | +58.4% |
TEVA leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
TEVA leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
TEVA is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than PRGO's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TEVA currently trades 96.4% from its 52-week high vs PRGO's 41.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.18x | 1.13x |
| 52-Week HighHighest price in past year | $28.44 | $37.35 |
| 52-Week LowLowest price in past year | $9.23 | $14.99 |
| % of 52W HighCurrent price vs 52-week peak | +41.2% | +96.4% |
| RSI (14)Momentum oscillator 0–100 | 60.9 | 73.5 |
| Avg Volume (50D)Average daily shares traded | 3.4M | 6.6M |
TEVA leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
PRGO leads this category, winning 1 of 1 comparable metric.
Analyst Outlook
Wall Street rates PRGO as "Hold" and TEVA as "Buy". Consensus price targets imply 70.6% upside for PRGO (target: $20) vs 8.3% for TEVA (target: $39). PRGO is the only dividend payer here at 9.81% yield — a key consideration for income-focused portfolios.
| Metric | PRGOPerrigo Company p… | TEVATeva Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $20.00 | $39.00 |
| # AnalystsCovering analysts | 36 | 46 |
| Dividend YieldAnnual dividend ÷ price | +9.8% | — |
| Dividend StreakConsecutive years of raises | 10 | 1 |
| Dividend / ShareAnnual DPS | $1.15 | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
PRGO leads this category, winning 1 of 1 comparable metric.
Key Takeaway
TEVA leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook).
Best OverallTeva Pharmaceutical Industr… (TEVA)Leads 4 of 6 categories
Loading custom metrics...
PRGO vs TEVA: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is PRGO or TEVA a better buy right now?
For growth investors, Teva Pharmaceutical Industries Limited (TEVA) is the stronger pick with 4.
3% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Teva Pharmaceutical Industries Limited (TEVA) offers the better valuation at 30. 0x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate Teva Pharmaceutical Industries Limited (TEVA) a "Buy" — based on 46 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PRGO or TEVA?
On forward P/E, Perrigo Company plc is actually cheaper at 5.
6x — notably different from the trailing picture, reflecting expected earnings growth.
03Which is the better long-term investment — PRGO or TEVA?
Over the past 5 years, Teva Pharmaceutical Industries Limited (TEVA) delivered a total return of +246.
2%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: TEVA returned -28. 3% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PRGO or TEVA?
By beta (market sensitivity over 5 years), Teva Pharmaceutical Industries Limited (TEVA) is the lower-risk stock at 1.
13β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 4% more volatile than TEVA relative to the S&P 500. On balance sheet safety, Perrigo Company plc (PRGO) carries a lower debt/equity ratio of 135% versus 2% for Teva Pharmaceutical Industries Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — PRGO or TEVA?
By revenue growth (latest reported year), Teva Pharmaceutical Industries Limited (TEVA) is pulling ahead at 4.
3% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Teva Pharmaceutical Industries Limited grew EPS 182. 8% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, TEVA leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PRGO or TEVA?
Teva Pharmaceutical Industries Limited (TEVA) is the more profitable company, earning 8.
2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 8. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TEVA leads at 12. 5% versus 8. 1% for PRGO. At the gross margin level — before operating expenses — TEVA leads at 51. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PRGO or TEVA more undervalued right now?
On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.
6x forward P/E versus 14. 5x for Teva Pharmaceutical Industries Limited — 9. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.
08Which pays a better dividend — PRGO or TEVA?
In this comparison, PRGO (9.
8% yield) pays a dividend. TEVA does not pay a meaningful dividend and should not be held primarily for income.
09Is PRGO or TEVA better for a retirement portfolio?
For long-horizon retirement investors, Perrigo Company plc (PRGO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
18), 9. 8% yield). Both have compounded well over 10 years (PRGO: -77. 7%, TEVA: -28. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PRGO and TEVA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PRGO is a small-cap income-oriented stock; TEVA is a mid-cap quality compounder stock. PRGO pays a dividend while TEVA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(PRGO: -7.2% · TEVA: 2.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.